Video

Dr. O'Reilly on Ongoing Trials With PARP Inhibitors in Pancreatic Cancer

Eileen O'Reilly, MD, Winthrop Rockefeller Endowed Chair in Medical Oncology, co-director, Medical Initiatives, David M. Rubenstein Center for Pancreatic Cancer Research, section head, Hepatopancreaticobilary and Neuroendocrine Cancers, and medical oncologist, Memorial Sloan Kettering Cancer Center, discusses

Eileen O'Reilly, MD, Winthrop Rockefeller Endowed Chair in Medical Oncology, co-director, Medical Initiatives, David M. Rubenstein Center for Pancreatic Cancer Research, section head, Hepatopancreaticobilary and Neuroendocrine Cancers, and medical oncologist, Memorial Sloan Kettering Cancer Center (MSKCC), discusses ongoing clinical trials with PARP inhibitors in pancreatic cancer.

The addition of a checkpoint inhibitor to a PARP inhibitor has been evaluated in breast and ovarian cancers, says O’Reilly. Similar combinations will be subject to investigation in pancreatic cancer. For example, one trial at MSKCC will open for patients with germline BRCA1/2 or PALB2 mutations, other DNA damage response and repair mutation genes, and those with platinum-sensitive disease.

Combinations with VEGF-targeted agents and PARP inhibitors, which have shown activity in ovarian cancer, is another area of interest, concludes O’Reilly.

Clinicians referring a patient to MSK can do so by visiting msk.org/refer, emailing referapatient@mskcc.org, or by calling 833-315-2722.
Related Videos
Aditya Bardia, MD, MPH, FASCO
Christina S. Baik, MD, MPH
Dana Zakalik, MD
David C. Fisher, MD
Kevin Kalinsky, MD, MS
Alberto Montero, MD, MBA, CPHQ
R. Lor Randall, MD, FACS
Daniel E. Haggstrom, MD
Jairam Krishnamurthy, MD, FACP
Yair Lotan, MD, professor, urology, chief, urologic oncology, Jane and John Justin Distinguished Chair in Urology, UT Southwestern Harold C. Simmons Comprehensive Cancer Center; medical director, Urology Clinic, UT Southwestern and Parkland Health and Hospital System